Advancing global antibiotic research, development and access

The global antibiotic crisis is causing a decline in private investment in research and development, leading to a shortage of antibiotics and inequitable access. Public and philanthropic funding is increasingly being used to support antibiotic R&D through nonprofit partnerships like CARB-X and GARDP. The urgency and commitment of world leaders are needed to fully support the antibiotic R&D ecosystem, incentivizing all sectors to conduct public health-driven R&D and make effective antibiotics accessible to all.